Alirocumab and Plaque Burden In Familial Hypercholesterolaemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT05465278

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Fundación Hipercolesterolemia Familiar (from the registry)
Registry
  • NCT NCT05465278
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05465278. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2022-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alirocumab and Plaque Burden In Familial Hypercholesterolaemia
Acronym
ARCHITECT
Intervention (Drug)
Alirocumab
Lead sponsor
Fundación Hipercolesterolemia Familiar (class: other)

Record details

Record id
cardio:ct-nct05465278
Content hash
8dda07eb72e1bce68ec281b9568d381f07e311636749606f27db68d55bf28b62